Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
History
Biology of the lysosome
Lysosomes and disease
Molecular pathogenesis
Disease progression
Presentation & progression
Disease management
Diagnosis & testing
Genetics
Summary of Product Characteristics
Gaucher
Fabry
MPS I
Pompe

 



 

Lysosomes and disease

Lysosomes are important in a variety of functions, including

Degradation of normal cellular proteins and other molecules (like DNA, RNA, lipids, or polysaccharides)
Disposal of abnormal proteins and other molecules
Renewal of intracellular structures (e.g. mitochondria)
Repair of plasma membrane
Release of endocytosed nutrients
Downregulation of surface receptors
Inactivation of pathogenic organisms
Antigen processing
Metal ion homeostasis
Cell death (apoptosis)

Primary as well as secondary dysfunction of lysosomes has now been recognized in a variety of diseases. Primary dysfunction is the result of a genetic defect in a protein that is directly needed in lysosomal functioning. See Molecular pathogenesis of lysosomal storage diseases.

Secondary dysfunction is increasingly recognized in a number of common diseases including Alzheimer’s disease and congestive heart failure as well as aging. Time-dependent intralysosomal accumulation of lipofuscin in non-dividing, long-lived cells is the most consistent morphologic change of aging. The mechanisms responsible for secondary lysosomal dysfunction remain poorly understood.

In case of (primary) lysosomal storage disorders, there is accumulating evidence that a defect of one specific lysosomal enzyme or function can induce subsequent defects and dysfunction within the lysosome. Consequently, the disease processes and disease progression might not be adequately predicted by assessing substrate storage and the direct impact thereof. See Disease progression

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with CerezymeŽ

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with FabrazymeŽ significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease